Assessment and characteristics of Erenumab therapy on migraine management.

Saeed, Haitham; Tulbah, Alaa S; Gamal, Amr; Kamal, Marwa

Saeed, Haitham; Tulbah, Alaa S; Gamal, Amr; Kamal, Marwa.

Afiliação

Saeed H; Clinical Pharmacy Department, Faculty of Pharmacy, Beni-suef University, Beni-suef, Egypt.
Tulbah AS; Department of Pharmaceutics, College of Pharmacy, Umm Al Qura University, Makkah, Saudi Arabia.
Gamal A; Department of Pharmaceutics, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt.
Kamal M; Clinical Pharmacy Department, Faculty of Pharmacy, Fayoum University, Fayoum, Egypt.

Saudi Pharm J ; 30(8): 1153-1158, 2022 Aug.

Article em En | MEDLINE | ID: mdl-36164568

Palavras-chave

Erenumab; Migraine; Triggers of migraine

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies Idioma: En Revista: Saudi Pharm J Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Egito

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google